<DOC>
	<DOCNO>NCT00982904</DOCNO>
	<brief_summary>This study aim assess tolerability pharmacokinetic parameter fexinidazole healthy volunteer . In animal model acute chronic experimental Trypanosomiasis infection , fexinidazole show highly promise efficacy .</brief_summary>
	<brief_title>Human African Trypanosomiasis : First Man Clinical Trial New Medicinal Product , Fexinidazole</brief_title>
	<detailed_description>The present study design obtain safety , tolerability PK data single multiple oral administration increase dos fexinidazole healthy male sub-Saharan African subject . This study also assess relative bioavailability fexinidazole administer tablet comparison oral suspension , assess impact concomitant food intake relative bioavailability fexinidazole single oral dose administration . The study divide 3 successive part . Study Part I randomize , double-blind , placebo-controlled , single ascend dose study fexinidazole administer oral suspension . Study Part II comparative bioavailability study fexinidazole tablet vs. oral suspension assessment food effect , accord three-way cross-over design . Clinical part conduct open condition bioanalysis blind condition . Study Part III randomize , double-blind , placebo-controlled , multiple ascend dose study fexinidazole administer either oral suspension tablet , depend Part II result . Dosage regimen either q.d . b.i.d. , depend Part I Part II result unchanged drug metabolite . Treatment duration 14 day . Bioanalysis perform open condition Study Part I Study Part III .</detailed_description>
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<criteria>All subject subSaharan African origin parent subSaharan African origin , Male subject body mass index ( BMI ) calculate weight kg/ ( height m2 ) 18 28 kg/m2 screening , Able communicate well Investigator research staff comply requirement entire study , Provision write informed consent participate show signature volunteer consent form , Light smoker ( less 5 cigarette per day ) subject nonsmoker . Normal arterial blood pressure ( BP ) pulse rate , abnormal , consider clinically significant principal Investigator . Registered French Social Security agreement French law biomedical experimentation . Who direct question physical examination evidence clinically significant acute chronic disease , include know suspected HIV , HBV HCV infection , Who previously receive fexinidazole , With clinically significant abnormality follow review prestudy laboratory test ( ASAT , ALAT ALP must within normal range ) , vital sign , full physical examination ECG , Who within exclusion period define National Register Healthy Volunteers French Ministry Health , Who forfeit freedom administrative legal award guardianship , Unwilling give inform consent , Who positive laboratory test Hepatitis B surface antigen ( HbsAg ) , antiHIV 1/2 anti HCV antibody Who history allergy , intolerance photosensitivity drug , Who history serious allergy , asthma , allergic skin rash sensitivity drug , Who know suspected alcohol drug abuser ( 14 unit alcohol per week , one unit = 8 g 10 mL pure alcohol ) , Who drink 8 cup daily beverage contain caffeine , Who positive laboratory test urine drug screening Who undergo surgery donate blood within 12 week prior start study , Who take prescribed counter drug ( include antacid drug ) , exception paracetamol ( 3 g per day ) within 2 week prior first dose administration , Who clinical condition prior therapy , opinion Investigator , make subject unsuitable study , Who participate clinical trial investigational drug past 3 month precede study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>neglect disease</keyword>
	<keyword>africa</keyword>
	<keyword>new drug</keyword>
	<keyword>oral drug</keyword>
	<keyword>parasite</keyword>
</DOC>